Life-Long Steroid Responsive Familial Myopathy With Docking Protein 7 Mutation

DOI Web Site 被引用文献1件
  • Shin J. Oh
    Department of Neurology, University of Alabama at Birmingham, Birmingham, AL; and
  • Peter H. King
    Department of Neurology, University of Alabama at Birmingham, Birmingham, AL; and
  • Alice Schindler
    Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.

抄録

<jats:title>Abstract</jats:title> <jats:p>Docking protein 7 (DOK7) congenital myasthenic syndrome (CMS) is characterized by limb-girdle weakness and lack of fluctuating fatigability simulating many familial myopathies. Albuterol is the first line of therapy in view of consistent improvement. Two brothers with progressive predominant biceps weakness for 1–3 years responded to prednisone treatment for 40–50 years. Various studies including muscle biopsy and many laboratory studies were unsuccessful for the definite diagnosis. Gene study, 40 years after the initial evaluation, confirmed the diagnosis of DOK7 CMS. These are the first reported cases of DOK7 CMS associated with a sustained benefit from corticosteroids.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ